A twice-yearly injectable drug for HIV prevention, lenacapavir, is a breakthrough advancement in public health. On Wednesday at AIDS 2024, the 25th International AIDS Conference, Linda-Gail Bekker presented the full results from the ‘PURPOSE 1’ trial of twice-yearly injectable lenacapavir for HIV prevention. The new data provides details on the efficacy, safety and tolerability of twice a year lenacapavir injections and were presented at a special late-breaking session at the conference. The data has also been published today in The New England Journal of Medicine. ”The results confirm that lenacapavir…